| Strive Health Midwest, Llc | |
|
1360 S 5th St Ste 268 Saint Charles MO 63301-2446 | |
| (314) 900-1112 | |
| Not Available |
| Full Name | Strive Health Midwest, Llc |
|---|---|
| Speciality | Clinic/Center |
| Location | 1360 S 5th St Ste 268, Saint Charles, Missouri |
| Authorized Official Name and Position | Aaron Molitor (COO) |
| Authorized Official Contact | 7202045760 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Strive Health Midwest, Llc 1600 Stout St Ste 2000 Denver CO 80202-3113 Ph: (720) 204-5760 | Strive Health Midwest, Llc 1360 S 5th St Ste 268 Saint Charles MO 63301-2446 Ph: (314) 900-1112 |
| NPI Number | 1306554811 |
|---|---|
| Provider Enumeration Date | 11/14/2022 |
| Last Update Date | 09/28/2023 |
| Medicare PECOS PAC ID | 8325419385 |
|---|---|
| Medicare Enrollment ID | O20230130002498 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306554811 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | (* (Not Available)) | Primary |
| Provider Name | Margaret Warner |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093843732 PECOS PAC ID: 3779552690 Enrollment ID: I20040928000705 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
| Provider Name | Christopher James Kersting |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1972169746 PECOS PAC ID: 8325371586 Enrollment ID: I20190715003093 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
| Provider Name | Lydia M Laughman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1396200481 PECOS PAC ID: 4880922483 Enrollment ID: I20190820004092 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
| Provider Name | Yolanda M Brown |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386107134 PECOS PAC ID: 6800128026 Enrollment ID: I20191021002502 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
| Provider Name | Allison R Loden |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1760144497 PECOS PAC ID: 1557756459 Enrollment ID: I20220310002507 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
| Provider Name | Ashley Roeding |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386987568 PECOS PAC ID: 0345489753 Enrollment ID: I20220617000328 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
| Provider Name | Alan Meisterman |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1770230625 PECOS PAC ID: 3971558693 Enrollment ID: I20220627003450 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
| Provider Name | Haley D Justus |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1861896672 PECOS PAC ID: 9638565633 Enrollment ID: I20220628000507 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
| Provider Name | Christine Gallup |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1083981831 PECOS PAC ID: 8224422597 Enrollment ID: I20220722002010 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
| Provider Name | Matthew J Kerr |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1659029585 PECOS PAC ID: 3476930371 Enrollment ID: I20230206001222 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
| Provider Name | Gina A Green |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083114730 PECOS PAC ID: 0941562284 Enrollment ID: I20230328002321 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
| Provider Name | Justin M Heinz |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1790302057 PECOS PAC ID: 8325401201 Enrollment ID: I20230824002792 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
| Provider Name | Vibhuti Patel |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1629723481 PECOS PAC ID: 6002200102 Enrollment ID: I20230914003510 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
| Provider Name | Alina Egolf |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1205550266 PECOS PAC ID: 3678939238 Enrollment ID: I20231116001587 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
| Provider Name | Heather L Palmer |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1760059125 PECOS PAC ID: 5799140588 Enrollment ID: I20240127000707 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
The world's first kidney transplant from a living HIV-positive donor to another HIV-positive person was successfully performed Monday by doctors at a Johns Hopkins University hospital.
Oncotarget published "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas" which reported that the incidence of human papillomavirus-positive head and neck squamous cell carcinoma has increased dramatically over the past decades due to an increase in infection of the oral mucosa by HPV.
› Verified 2 days ago
Compass Health, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2645 Muegge Rd, Saint Charles, MO 63303 Phone: 844-853-8937 | |
Compass Health, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3075 New Town Blvd, Saint Charles, MO 63301 Phone: 888-403-1071 | |
Visionary Cts Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1551 Wall St Ste 120, Saint Charles, MO 63303 Phone: 636-219-0177 Fax: 636-493-1002 | |
Pathways Community Behavioral Healthcare Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 102 Compass Point Dr, Saint Charles, MO 63301 Phone: 888-403-1071 | |
Wuca - Northwest Pediatrics Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 11 Garvey Pkwy, Saint Charles, MO 63303 Phone: 636-441-7280 | |
Lauer Chiropractic Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2241 Bluestone Dr, Saint Charles, MO 63303 Phone: 636-940-2226 Fax: 636-940-9990 | |
Visionary Vaccination & Health Services Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2757 Plaza Way, Saint Charles, MO 63303 Phone: 636-493-0219 |